Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
Clearbridge HealthFRA:5C6 3-Year RORE % is -75.00 as of Jun. 2026. The stock has 4 warning signs investors should review. Among 200 Medical Diagnostics & Research companies, Clearbridge Health ranks worse than 87.5% on this metric.
Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments.
Clearbridge Health's 3-Year RORE % for the quarter that ended in Jun. 2026 was -75.00%.
The industry rank for Clearbridge Health's 3-Year RORE % or its related term are showing as below:
FRA:5C6's 3-Year RORE % is ranked worse than 87.5% of 200
companies
in the Medical Diagnostics & Research industry
Industry Median: -9.49
vs FRA:5C6: -75.00
Clearbridge Health (FRA:5C6) 3-Year RORE % Explanation
Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.
There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 3-year period is chosen.
Be Aware
Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.
Clearbridge Health 3-Year RORE % Related Terms
Clearbridge Health 3-Year RORE % Historical Data
* Premium members only.
The historical data trend for Clearbridge Health's 3-Year RORE % can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:5C6 vs TMO, DHR, IDXX: 3-Year RORE % Comparison
For the Diagnostics & Research subindustry, Clearbridge Health's 3-Year RORE %, along with its competitors' market caps and 3-Year RORE % data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Clearbridge Health 3-Year RORE % vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Clearbridge Health's 3-Year RORE % distribution charts can be found below:
* The bar in red indicates where Clearbridge Health's 3-Year RORE % falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
In the calculation of 3-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Jun. 2026 and 3-year before.
Clearbridge Health (FRA:5C6) has a 3-Year RORE % of -75.00 as of Jun. 2026. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Clearbridge Health and its competitors. According to the industry distribution chart, Clearbridge Health ranks #175 out of 200 companies in the Medical Diagnostics & Research industry, placing it in the top 87.5%.
Is Clearbridge Health's 3-Year RORE % too high?
Clearbridge Health's current 3-Year RORE % is -75.00. Based on the distribution chart, Clearbridge Health ranks #175 out of 200 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers.
How does Clearbridge Health's 3-Year RORE % compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Clearbridge Health ranks #175 out of 200 companies for 3-Year RORE %. This places Clearbridge Health in the lower half of its industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good 3-Year RORE % for a Medical Diagnostics & Research company?
A good 3-Year RORE % depends on the Medical Diagnostics & Research industry context. However, 3-Year RORE % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high 3-Year RORE % mean?
A high 3-Year RORE % can signal that a stock is expensive relative to its fundamentals. 3-Year RORE % shows how much a company earns by reinvesting its retained earnings in 3-year. View historical data on Clearbridge Health and its competitors. Clearbridge Health's current 3-Year RORE % is -75.00. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Clearbridge Health stock overvalued right now?
Clearbridge Health (FRA:5C6) has a current 3-Year RORE % of -75.00. The current 3-Year RORE % is -75.00. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is 3-Year RORE % calculated?
3-Year RORE % is calculated from a company's financial statements. For Clearbridge Health (FRA:5C6), the current 3-Year RORE % is -75.00 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Clearbridge Health Ltd provides health care services. It is an integrated healthcare group with end-to-end diagnostic abilities, deploying non-invasive tests to identify and manage illness. The segments are Strategic investments; Others ; Medical clinics; Corporate segment and Investment. It derives key revenue from the Medical clinics segment. The medical clinics/centres segment involves the provision of general medical, dental and clinical services and distribution of the medical and pharmaceutical products. The group has a business presence in Singapore, Philippines, Hong Kong, Malaysia and others.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:5C6 has been successfully added to your 
